A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the Prevention of Episodic Cluster Headache
Sponsor: |
Teva Branded Pharmaceutical Products, R&D Inc. |
Enrolling: |
Male and Female Patients |
Study Length: |
16 Weeks |
Clinic Visits: |
5 |
IRB Number: |
AAAR1517 |
U.S. Govt. ID: |
NCT02945046 |
Contact: |
Marianna Yugrakh, MD: (212) 305-6876 / ms3006@cumc.columbia.edu |
The ENFORCE Teva Cluster Headache clinical trial is looking for people who have been diagnosed with episodic cluster headaches to participate. People who volunteer and qualify may have the opportunity to try an investigational study drug for cluster headaches. If you're 18 to 70 years old and have experienced cluster headaches for 12 months or more, you may be able to enroll. In this clinical research study, you may receive investigational study drug or may receive a placebo based on treatment group randomization. You'll also receive study-related care from the principal investigator and possible compensation for travel. The study doctor will also check other requirements to see if you're eligible to participate. This trial runs for 16 weeks and requires 5 visits to our clinic at the Columbia University Medical Center. Typical visit procedures include blood tests, physical exam, medical questionnaires, and an EKG.
This study is closed
Investigator
Marianna Shnayderman Yugrakh, MD
Are you 18 to 70 years of age? |
Yes |
No |
Have you been getting cluster headaches for at least 12 months? |
Yes |
No |